URG4 inhibitors encompass a distinct class of chemical compounds designed to selectively impede the function of the URG4 protein, a factor implicated in various cellular processes. The inhibition of URG4 affects cellular mechanisms at a molecular level by disrupting specific signaling pathways that URG4 typically influences. URG4, also known as up-regulated gene 4, plays a role in cellular proliferation and survival, and its overexpression has been noted in certain cell lines, indicating its potential role in promoting oncogenic processes. Inhibitors targeting URG4 may work by attaching to the active site or a regulatory domain of the protein, thereby altering its conformation and function. This type of inhibition can prevent URG4 from interacting with its substrates or partners, effectively shutting down the signaling pathways in which it is involved. The inhibitors may be small molecules that have been identified through high-throughput screening, or they could be designed based on the structure of the URG4 protein to ensure a high specificity and affinity for their target.
The biochemical mechanisms of action for URG4 inhibitors are complex and depend on the nature of the inhibitor and the biological context. Some inhibitors might block the ATP binding site of URG4, which is essential for its activity, while others might interfere with the protein's ability to undergo necessary post-translational modifications or to translocate to specific cellular compartments where it exerts its function. The specificity of URG4 inhibitors is critical, as it ensures minimal off-target effects and allows for a more precise understanding of the protein's role in cellular pathways. By studying the effects of these inhibitors on cells, researchers can elucidate the biological functions of URG4, such as its involvement in cell cycle regulation, apoptosis, or DNA repair mechanisms. These investigations contribute to a broader comprehension of how cells maintain homeostasis and respond to internal and external stimuli, with the inhibition of URG4 providing insights into the fine-tuning of cellular responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases, including PKC, which can affect the PI3K/Akt signaling pathway. As URG4 is known to be upregulated by PI3K/Akt pathway, staurosporine can indirectly lead to the decreased activity of URG4 by inhibiting this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3Ks. By blocking the PI3K/Akt pathway, it leads to a reduction in URG4 activity, as the PI3K/Akt pathway is crucial for URG4 upregulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the pathway, leading to a decrease in URG4 activity due to reduced signaling through PI3K/Akt that is known to enhance URG4 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, a downstream target of PI3K/Akt signaling. Since URG4 is known to be upregulated by the PI3K/Akt/mTOR pathway, rapamycin can decrease URG4 activity by inhibiting mTOR. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 indirectly reduces URG4 activity, as the MAPK pathway can contribute to URG4 upregulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. Inhibition of JNK can lead to reduced activity of URG4 by decreasing signaling through the MAPK pathway which may contribute to URG4 expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets RAF, thereby inhibiting the RAF/MEK/ERK pathway. This can lead to a decrease in URG4 activity because the RAF/MEK/ERK pathway has been implicated in URG4 upregulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can lead to decreased activity of URG4, as this pathway may play a role in the regulation of URG4 expression. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Since EGFR signaling can enhance URG4 expression, erlotinib can indirectly decrease URG4 activity by inhibiting EGFR. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is another EGFR tyrosine kinase inhibitor, which can lead to a reduction in URG4 activity by blocking the EGFR signaling pathway that is known to upregulate URG4. | ||||||